In a press release, the company indicates that it is currently in discussions with a potential partner for funding that could enable it to invest in the development of a second generation vaccine.
The company had previously made the advancement of this project conditional on obtaining the necessary financing or a financing commitment during the third quarter of 2022.
As the end of the quarter approaches, Valneva – which does not reveal the identity of its interlocutor – says that it is conducting “active” discussions that will probably continue over the coming months.
The vaccine specialist acknowledges, however, that these talks may not lead to an agreement.
‘Although nothing has been specified, we think it possible that it may be companies that offer financing solutions via debt or equity lines’, commented this morning the analysts at Invest Securities.
In parallel, Valneva says it is continuing its discussions with various governments and regulatory authorities around the world, with the aim of deploying the remaining stocks of its first inactivated vaccine within the next twelve months.
The company also plans to publish additional clinical data by the end of the year, including heterologous recall data, which could potentially support the disposal of its inventories.
In the wake of this information, Valneva shares climbed 6.2% on Monday in the first exchanges. The title is still 76% down since the start of the year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.